Clark Mitchall G. 4
4 · Atara Biotherapeutics, Inc. · Filed May 16, 2018
Insider Transaction Report
Form 4
Clark Mitchall G.
Chief R & QA Officer
Transactions
- Sale
Common Stock
2018-05-16$46.30/sh−300$13,890→ 133,832 total - Sale
Common Stock
2018-05-16$46.04/sh−4,347$200,136→ 134,132 total - Exercise/Conversion
Restricted Stock Units
2018-05-15−4,808→ 0 total→ Common Stock (4,808 underlying) - Exercise/Conversion
Common Stock
2018-05-15+4,808→ 138,479 total
Footnotes (6)
- [F1]Shares issued upon settlement of vested restricted stock units ("RSUs").
- [F2]Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.25 to $46.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- [F5]The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.
- [F6]The earlier of (i) March 27, 2021 or (ii) the recepient's termination date.